Evidence map›Paper›PMID 31933992›Full record

ArticleInternational journal of clinical and experimental pathology2019

Epithelioid inflammatory myofibroblastic sarcoma of stomach: diagnostic pitfalls and clinical characteristics.

Pei Xu, Pingping Shen, Yangli Jin, Li Wang, Weiwei Wu

Open access · greenAbstract read
PubMed Full text at PMC
In one paragraph

Article in International journal of clinical and experimental pathology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Pei XuDepartment of Burns, Ningbo Huamei Hospital, University of Chinese Academy of Science (Ningbo No. 2 Hospital) Ningbo, China.
Pingping ShenDepartment of Gastroenterology, Yinzhou Second Hospital Ningbo, China.
Yangli JinDepartment of Ultrasonography, Yinzhou Second Hospital Ningbo, China.
Li WangDepartment of Pathology, Clinical Pathological Diagnosis Center Ningbo, China.
Weiwei WuDepartment of Burns, Ningbo Huamei Hospital, University of Chinese Academy of Science (Ningbo No. 2 Hospital) Ningbo, China.
Ningbo No. 2 Hospital · CNPathological Society · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Inflammatory myofibroblastic tumor (IMT) is a neoplasm composed of spindled neoplastic myofibroblasts admixed with reactive lymphoplasmacytic cells, plasma cells, and/or eosinophils, which has an intermediate biological behavior. An IMT variant with plump round epithelioid or histiocytoid tumor cells, recognized as epithelioid inflammatory myofibroblastic sarcoma (EIMS), has a more clinically aggressive progression. To the best of our knowledge, only about 40 cases of EIMS have previously been reported in limited literature. Here, we report here a case of unusual EIMS with a relative indolent clinical behavior. We reviewed the literature for 18 similar cases. The patients present with a highly aggressive inflammatory myofibroblastic tumor characterized by round or epithelioid morphology, prominent neutrophilic infiltrate, and positive staining of ALK with RANBP2-ALK gene fusion or RANBP1-ALK gene fusion, or EML4-ALK gene fusion. Our case is the first case of primary stomach EIMS. Moreover, the mechanisms of the rare entity have not been widely recognized and require further study. Early accurate diagnosis and complete resection of this tumor is necessary. Some researchers suggest expression of PD-L1 may provide new strategies for ALK-targeted therapy.

Indexed as

epithelioid inflammatory myofibroblastic sarcomaimmunostainingInflammatory myofibroblastic tumormorphologypoor prognosisRANBP1-ALK gene fusionRANBP2-ALK gene fusion

Identifiers

PMID31933992
PMCPMC6947137
OpenAlexW3007978742

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.